Form D · Biotechnology

Camp4 Therapeutics Corp

Cambridge, MA · CIK 0001736730

Offering snapshot reported Jun 21, 2022 · SEC filing

Reported sold
$100M
Indefinite offering
Investors reported
16
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 3, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 21, 2022Initial$100,494,015No comparison16SEC filing
Oct 29, 2021Amendment$44,999,960$29,999,960vs Mar 19, 20217SEC filing
Mar 19, 2021Initial$15,000,000No comparison7SEC filing
Sep 25, 2018Initial$34,080,628No comparison6SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-449708

Source: Form D, filed Jun 21, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Ann Barbier Executive
James Boylan Director
David Bumcrot Executive
Jorge Conde Director
Shaan Gandhi Director
Michelle Gates Executive
Kelly Gold Executive
Michael Higgins Director
Steve Holtzman Director
Josh Mandel Brehm Director, Executive
Caleb Moore Executive
Amir Nashat Director
Paula Ragan Director
Andy Schwab Director
Andrew J. Schwab Director
Alfica Sehgal Executive
Ravi I. Thadhani Director
Richard Young Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
One Kendall Square Building 1400 West, 3 Rd Floor
Cambridge, MA, 02139